Literature DB >> 11306876

The progression of benign prostatic hyperplasia: examining the evidence and determining the risk.

J B Anderson1, C G Roehrborn, J A Schalken, M Emberton.   

Abstract

BACKGROUND: Benign prostatic hyperplasia (BPH) is often associated with enlargement of the prostate gland, lower urinary tract symptoms, decreased urinary flow and a reduced quality of life. Furthermore, if the symptoms associated with BPH are left untreated, serious complications, such as acute urinary retention, may ensue. Evidence is emerging from long-term clinical studies to suggest that BPH is a progressive disease, with some patients progressing much more rapidly than others.
OBJECTIVE: This article aims to explore the natural history of BPH progression from a molecular, pathological and clinical perspective, with emphasis on the key clinical evidence to support the progressive nature of this disease. How our increased understanding of the disease and of the risk factors for BPH progression might be applied to improve current management practices are also discussed.
CONCLUSION: Strategies to identify patients most at risk and guidelines directed towards long-term management, in addition to short-term treatment, may be useful in helping to prevent BPH progression.

Entities:  

Mesh:

Year:  2001        PMID: 11306876     DOI: 10.1159/000052475

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  32 in total

1.  [Urological illnesses in the elderly].

Authors:  J M Wolff
Journal:  Urologe A       Date:  2004-08       Impact factor: 0.639

2.  2010 Update: Guidelines for the management of benign prostatic hyperplasia.

Authors:  J Curtis Nickel; Carlos E Méndez-Probst; Thomas F Whelan; Ryan F Paterson; Hassan Razvi
Journal:  Can Urol Assoc J       Date:  2010-10       Impact factor: 1.862

3.  Antioxidant levels of common fruits, vegetables, and juices versus protective activity against in vitro ischemia/reperfusion.

Authors:  Holly Bean; Catherine Schuler; Robert E Leggett; Robert M Levin
Journal:  Int Urol Nephrol       Date:  2009-09-19       Impact factor: 2.370

4.  [Diagnostic and differential diagnosis of benign prostate syndrome (BPS): guidelines of the German Urologists].

Authors:  R Berges; K Dreikorn; K Höfner; S Madersbacher; M C Michel; R Muschter; M Oelke; O Reich; W Rulf; C Tschuschke; U Tunn
Journal:  Urologe A       Date:  2009-11       Impact factor: 0.639

5.  Canadian Urological Association guideline on male lower urinary tract symptoms/benign prostatic hyperplasia (MLUTS/BPH): 2018 update.

Authors:  J Curtis Nickel; Lorne Aaron; Jack Barkin; Dean Elterman; Mahmoud Nachabé; Kevin C Zorn
Journal:  Can Urol Assoc J       Date:  2018-10       Impact factor: 1.862

Review 6.  [Diagnostics of benign prostate syndrome].

Authors:  M Seitz; A Herlemann; G Magistro; C G Stief
Journal:  Urologe A       Date:  2013-02       Impact factor: 0.639

7.  Associations between variants in the cyclooxygenase 2 enzyme gene (PTGS2) and development of benign prostate enlargement.

Authors:  Jennifer L St Sauver; Michael M Lieber; Susan L Slager; Debra J Jacobson; Michaela E McGree; Steven J Jacobsen
Journal:  BJU Int       Date:  2011-04-11       Impact factor: 5.588

8.  Age-related changes in prostate zonal volumes as measured by high-resolution magnetic resonance imaging (MRI): a cross-sectional study in over 500 patients.

Authors:  Baris Turkbey; Robert Huang; Srinivas Vourganti; Hari Trivedi; Marcelino Bernardo; Pingkun Yan; Compton Benjamin; Peter A Pinto; Peter L Choyke
Journal:  BJU Int       Date:  2012-09-14       Impact factor: 5.588

Review 9.  Predictive medicine in non-malignant urological disorders.

Authors:  Mariangela Mancini; Antonio Cisternino; Ivan Matteo Tavolini; Fabrizio Dal Moro; Pierfrancesco Bassi
Journal:  World J Urol       Date:  2003-12-20       Impact factor: 4.226

10.  Finasteride in the treatment of patients with benign prostatic hyperplasia: a review.

Authors:  Angela B Smith; Culley C Carson
Journal:  Ther Clin Risk Manag       Date:  2009-07-12       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.